Persistence with Treatment in Newly Treated Middle-Aged Patients with Essential Hypertension

Abstract

Barriers to persistence occur early in the course of therapy, and adherence continues to decline over a period of 3 years. Patients were least persistent to diuretic therapy.

A Simplified Approach to the Treatment of Uncomplicated Hypertension

“…[1][2][3] An important part of this problem is current prescribing practices. Unfortunately, most patients require Ն2 medications to achieve optimal control, 4 and these multidrug regimens are associated with lower adherence.…”

Relationship of the Magnitude of Member Cost-Share and Medication Persistence With Newly Initiated Renin Angiotensin System Blockers

“…Combination products were excluded because the single angiotensin system-blocking agents area ssociated with significantly higher persistence rates than other antihypertensive drug classes. 36 By limiting the analysis to single-agent angiotensin system blockers, we reduce the potential for agents such as hydrochlorothiazide in combination products to negatively influence persistence. An ew user was defined as an individual who started treatment with ACEI (Medi-Span' s6 -digit Generic Product Identifier [GPI] code 361000) or ARB (code 361500) single agents (excluding ACEI/ calcium channel blockers, ACEI/hydrochlorothiazide, and ARB/ hydrochlorothiazide combinations) between January1 ,2 004 and June 30, 2004 with no ACEI or ARB single agents or combinations dispensed in the 6m onths (180 days) preceding the index date.…”

“…[6][7]23,25,[31][32][33]36,[38][39][40][41] Andersen' sm odel was originally developed in the late 1960s to explain how and why families use health services. This model has since been adapted to predict and explain prescription drug use.…”

“…Some empirical studies have shown that age and race were significant predictors of medication persistence. 31,36,38,[40][41] Benner et al, for example, reported that members of black and other nonwhite races werel ess persistent with statin therapy. 41 Although we also found as ignificant association between persistence and race, this finding should be interpreted cautiously.B ecause claims data do not include race at the individual level, we measured race at an aggregate level (i.e., percentage of population in the patient' sZ ip Code area selfreporting white as their only racial group).…”

Is It Possible to Improve the Adherence to Treatment of Hypertension and Dyslipidemia in Patients Without Clinical Manifestations of Atherosclerosis?

“…В связи с этим на современном этапе активно изучаются различные пути повышения приверженности антигипертензивной терапии. Среди факторов, спо-собных повышать приверженность проводимой те-рапии, большое значение уделяется информирован-ности больных об их заболевании, особенностях течения, терапии, необходимости лечения артери-альной АГ, ее осложнениях, а также о последствиях низ-кой приверженности [14,15]. В этом отношении за-служивает внимания электронная версия SCORE, ко-торая позволяет в режиме online не только быстро оце-нить суммарный риск, но и может повысить мотива-цию пациентов к медикаментозной и немедикамен-тозной терапии.…”